MedTrace Logo

The EVOLVE China Clinical Trial

NCT01966159 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 412

Last updated 2023-11-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and effectiveness of the SYNERGY™ Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by visual estimate) in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate)

Conditions

Interventions

DEVICE

SYNERGY Investigational Device

percutaneous coronary intervention

DEVICE

PE Plus Investigational Device

percutaneous coronary intervention

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Yaling Han, Dr. · Shenyang Northern Hospital (The General Hospital of Shenyang Military Region)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-07-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01966159 on ClinicalTrials.gov